RBPMS2: A Potential Drug Target and Biomarker (G348093)

Target Name: RBPMS2

NCBI ID: G348093

RBPMS2

Other Name(s): RNA binding protein with multiple splicing 2 | RBPMS2 variant 1 | RBPS2_HUMAN | RNA binding protein, mRNA processing factor 2, transcript variant 1 | RNA binding protein, mRNA processing factor 2 | RNA-binding protein with multiple splicing 2

RBPMS2: A Potential Drug Target and Biomarker

Ribonucleoprotein (RNA) binding proteins (RBPMS2) are a family of transmembrane proteins that play a crucial role in various cellular processes, including gene regulation, RNA homeostasis, and cellular signaling. These proteins have been identified as potential drug targets and biomarkers due to their Involved in various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

The RBPMS2 gene is located on chromosome 18q and encodes a protein with 215 amino acid residues. The protein has a unique structure, with a long N-terminal region that includes a nucleotide-binding oligomerization domain (NBO), a zinc finger, and a carboxy-terminal region. The NBO is a conserved structure that is known to play a critical role in RNA binding, while the zinc finger and carboxy-terminal regions are involved in protein-protein interactions and localization to the cell membrane.

RBPMS2 is a protein that has been expressed in various cell types, including human embryonic stem cells, neurons, and tissues. It has been shown to play a role in various cellular processes, including cell signaling, cell division, and tissue repair. In addition , RBPMS2 has been shown to interact with various proteins, including RNA factors that regulate gene expression, such as RNA-protein interactions and post-transcriptional modification (PTM) enzymes.

As a potential drug target, RBPMS2 has been identified as a target for small molecules, including inhibitors of the NBO domain, which have been shown to inhibit the protein's RNA binding activity. In addition, studies have shown that inhibition of RBPMS2 can lead to various cellular consequences, including increased cell proliferation, enhanced angiogenesis, and decreased tissue repair.

In addition to its potential as a drug target, RBPMS2 has also been identified as a potential biomarker for various diseases, including cancer. Studies have shown that RBPMS2 is expressed in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, RBPMS2 has been shown to be involved in the regulation of cellular processes that are associated with cancer progression, including cell migration, invasion, and angiogenesis.

In conclusion, RBPMS2 is a protein that has been identified as a potential drug target and biomarker. Its unique structure and various cellular functions make it an attractive target for small molecules, and its involvement in various diseases make it a promising biomarker for the diagnosis and treatment of cancer and other diseases. Further research is needed to fully understand the role of RBPMS2 in various cellular processes and its potential as a drug and biomarker.

Protein Name: RNA Binding Protein, MRNA Processing Factor 2

Functions: RNA-binding protein involved in the regulation of smooth muscle cell differentiation and proliferation in the gastrointestinal system (PubMed:25064856). Binds NOG mRNA, the major inhibitor of the bone morphogenetic protein (BMP) pathway. Mediates an increase of NOG mRNA levels, thereby contributing to the negative regulation of BMP signaling pathway and promoting reversible dedifferentiation and proliferation of smooth muscle cells (By similarity)

The "RBPMS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBPMS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets